Concerned all centres in all countries. The main changes were: - To document that in the event of anaphylaxis, the study drug was to be stopped immediately and permanently. - To update the selection criteria No. 11, regarding patients with a positive interferon-γ-released assay (IGRA). - A new selection criteria had been added for patients considered as exposed to tuberculosis. - A new section in the protocol for having a benefit/risk assessment for the current clinical study had been added. - To add a new paragraph in the protocol (in order to warrant the patient’s safety), related to the therapeutic monitoring of therapies with a narrow therapeutic index being CYP450 and/or transporter substrates when initiating gevokizumab treatment.

Concerned all centres in all countries. The main objective of this Amendment was to add an open label treatment period of 24 weeks after the end of the planned double-blind 24-week period.

Concerned all centres in all countries. The main changes were: - Eligibility requirements for patients with indeterminate QuantiFERON®-TB test result at Selection visit: no evidence of active Tuberculosis (TB), agreement of a TB expert was to be obtained, - Eligibility requirements for patients with positive QuantiFERON®-TB test result at Selection visit: precision on the duration of the prophylactic TB treatment, - Modified selection criteria: disease duration ≤ 10 years, - Modified selection criteria: if CK and/or Aldolase ≤ 2 ULN and neither muscle biopsy nor Magnetic Resonance Imaging (MRI) ≤ 3 months was available, a MRI was authorized for the assessment of disease activity (edema and inflammatory changes). In this case the delay between selection and inclusion visit could be more than to 2 weeks, - Modified non selection criteria: the re-selection of a patient was authorized (no more than once) in case of a change in his clinical situation or of an infection or personal reason that temporarily avoided his inclusion, - Non participation of France to the open-label period of the study, due to Ethics Committee refusal for amended protocol n°2 (20 Septembre 2013), - For German sites only: additional safety measurements at visits W36 and W44 in order to satisfy Ethics Committee requirements for amended protocol n°2 (20 Septembre 2013), - For the United Kingdom (UK), the chest X-ray at W24 should not be performed in line with UK usual practice, for patients who performed the open-label period, - New laboratory (Biostorage) was added to the “Non sponsor parties” for the storage of pharmacogenomics, other omics and retrospective analysis samples at the end of the study,

Concerned all centres in all countries. The main changes were the following: - Modification in the definition of corticoresistance and corticodependence to be in compliance with current clinical practice. - Deletion of the criterion “Disease diagnosis duration < 10 years”. Disease duration became indefinite. - To allow the selection/inclusion of patients with dermatomyositis (DM) sine dermatitis (DM without cutaneous signs). These patients were initially not eligible, but as the disease is well-described in the literature and is a sub-group of DM, and in order to extend the possibility of an alternative treatment to this population in need, the efficacy of gevokizumab could also be assessed in this disease within the framework of the study. For these patients, the diagnosis should have been confirmed by the Adjudication Committee of the study before the inclusion of the patient. - Extension of the study population to patients with necrotizing autoimmune myopathy (NAM).